Thera-SAbDab

LIGELIZUMAB

> Structural Summary

Therapeutic	Ligelizumab
Target	IGHE
Heavy Chain	QVQLVQSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGTFTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS
Light Chain	EIVMTQSPATLSVSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIK
100% seqID Fv Structure	6uqr [Fvs: AC]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	6uqr [Fvs: AC]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Phase-III
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2012
INN Year Recommended	2013
Companies Involved	Novartis, Tanox
Conditions Approved	na
Conditions Active	Urticaria, Allergic asthma, Atopic dermatitis, Bullous pemphigoid
Conditions Discontinued	Hypersensitivity
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]